Sunday, May 01, 2022 8:07:45 PM
They sold the treatment center in Canada and retained the property in 2017. They brought those funds to Florida and in a relatively short period racked up an accumulated deficit of over $45 million by the end of 2019. That debt after the closure of the ARIA facility at 5400 East Avenue, West Palm Beach. That debt was restructured and is detailed in the 31 documents of the December 2020 8K. That debt is what has run the share count up and continues to be a serious problem.
December 2020 debt restructuring 8K
https://sec.report/Document/0001721868-20-000600/
2019 annual 10K filing
https://sec.report/Document/0001721868-20-000304/
Operating loss
The operating loss was $4,199,735 and $2,884,317 for the years ended December 31, 2019 and 2018, respectively, an increase of $1,315,418 or 45.6%. The increase is attributable to the decreased revenues and the movements in operating expenses discussed above.
Net loss
Net loss of $(14,962,841) and $(8,178,643) for the years ended December 31, 2019 and 2018, respectively, an increase of $6,784,198 or 83.0%, is primarily due to the increase in operating expenses in the current year, the loss on the sale of assets, the loss on debt conversions, the penalty on convertible notes and the deposit forfeited, offset by the increased credit on the derivative liability movement during the current year.
Going Concern
...As described in Note 3 to the consolidated financial statements, the Company had accumulated deficit of approximately $45.5 million and negative working capital of approximately $18.3 million at December 31, 2019, which raises substantial doubt about its ability to continue as a going concern...
Everything that I post is just my informed opinion and is simply an invitation to debate. Trade on your own due diligence please..
Recent GRST News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:45:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 09:54:23 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:04:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:55:26 PM
- Form 1-A POS - • Edgar (US Regulatory) • 10/20/2023 07:29:40 PM
- Form 1-A POS - • Edgar (US Regulatory) • 08/29/2023 07:21:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:37:36 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 12:43:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 04:51:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2023 06:56:41 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM